The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Open accessAbstract
Inadequate dosing and incomplete treatment regimens, coupled with the ability of the tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have fueled the rise of multidrug-resistant tuberculosis (MDR-TB). Treatment of MDR-TB infections is a major clinical challenge that has few viable or effective solutions; therefore patients face a poor prognosis and years of treatment. This review focuses on emerging drug classes that have the potential for treating MDR-TB and highlights their particular strengths as leads including their mode of action, in vivo efficacy, and key medicinal chemistry properties. Examples include the newly approved drugs bedaquiline and delaminid, and other agents in clinical and late preclinical development pipeline for the treatment of MDR-TB. Herein, we discuss the challenges to developing drugs to treat tuberculosis and how the field has adapted to these difficulties, with an emphasis on drug discovery approaches that might produce more effective agents and treatment regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“Through the growth of drug-resistant mutants, it was discovered that the rotor ring of the organism's F0F1 ATP synthase was the target, specifically binding to the c subunit [25].”
BackgroundDrug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans
Comas, I., Coscolla, M., Luo, T., Borrell, S., Holt, K. E., Kato-Maeda, M., Parkhill, J., Malla, B., Berg, S., Thwaites, G., et al. (2013) · Nature Genetics · doi:10.1038/ng.2744 · Cited by 1,025
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407426 · Cited by 645
An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site
Rock, F. L., Mao, W., Yaremchuk, A., Tukalo, M., Crépin, T., Zhou, H., Zhang, Y.-K., Hernandez, V., Akama, T., Baker, S. J., et al. (2007) · Science · doi:10.1126/science.1142189 · Cited by 631
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Lee, M., Lee, J., Carroll, M. W., Choi, H., Min, S., Song, T., Via, L. E., Goldfeder, L. C., Kang, E., Jin, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201964 · Cited by 560
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 544
Totally Drug-Resistant Tuberculosis in India
Udwadia, Z. F., Amale, R. A., Ajbani, K. K., & Rodrigues, C. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir889 · Cited by 527
Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis
Hugonnet, J.-E., Tremblay, L. W., Boshoff, H. I., Barry, C. E., & Blanchard, J. S. (2009) · Science · doi:10.1126/science.1167498 · Cited by 494
Evolution and transmission of drug-resistant tuberculosis in a Russian population
Casali, N., Nikolayevskyy, V., Balabanova, Y., Harris, S. R., Ignatyeva, O., Kontsevaya, I., Corander, J., Bryant, J., Parkhill, J., Nejentsev, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2878 · Cited by 473
The association between sterilizing activity and drug distribution into tuberculosis lesions
Prideaux, B., Via, L. E., Zimmerman, M. D., Eum, S., Sarathy, J., O'Brien, P., Chen, C., Kaya, F., Weiner, D. M., Chen, P.-Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3937 · Cited by 461
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
Drug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 432
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Dartois, V. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3200 · Cited by 388
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
Makarov, V., Lechartier, B., Zhang, M., Neres, J., van der Sar, A. M., Raadsen, S. A., Hartkoorn, R. C., Ryabova, O. B., Vocat, A., Decosterd, L. A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303575 · Cited by 380
Contribution of the Mycobacterium tuberculosis MmpL Protein Family to Virulence and Drug Resistance
Domenech, P., Reed, M. B., & Barry, C. E. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3492-3501.2005 · Cited by 361
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., & Nunn, A. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70328-1 · Cited by 342
Rawat, R., Whitty, A., & Tonge, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235848100 · Cited by 330
Targeting DnaN for tuberculosis therapy using novel griselimycins
Kling, A., Lukat, P., Almeida, D. V., Bauer, A., Fontaine, E., Sordello, S., Zaburannyi, N., Herrmann, J., Wenzel, S. C., König, C., et al. (2015) · Science · doi:10.1126/science.aaa4690 · Cited by 316
Preiss, L., Langer, J. D., Yildiz, Ö., Eckhardt-Strelau, L., Guillemont, J. E. G., Koul, A., & Meier, T. (2015) · Science Advances · doi:10.1126/sciadv.1500106 · Cited by 293
Mass spectrometry imaging for drug distribution studies
Prideaux, B., & Stoeckli, M. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.07.028 · Cited by 279
Cohen, K. A., Abeel, T., Manson McGuire, A., Desjardins, C. A., Munsamy, V., Shea, T. P., Walker, B. J., Bantubani, N., Almeida, D. V., Alvarado, L., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001880 · Cited by 274
VanderVen, B. C., Fahey, R. J., Lee, W., Liu, Y., Abramovitch, R. B., Memmott, C., Crowe, A. M., Eltis, L. D., Perola, E., Deininger, D. D., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004679 · Cited by 263
Inhibiting Bacterial Fatty Acid Synthesis
Zhang, Y.-M., White, S. W., & Rock, C. O. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600004200 · Cited by 263
Prideaux, B., Dartois, V., Staab, D., Weiner, D. M., Goh, A., Via, L. E., Barry, C. E., & Stoeckli, M. (2011) · Analytical Chemistry · doi:10.1021/ac1029049 · Cited by 260
Fumarate Reductase Activity Maintains an Energized Membrane in Anaerobic Mycobacterium tuberculosis
Watanabe, S., Zimmermann, M., Goodwin, M. B., Sauer, U., Barry, C. E., & Boshoff, H. I. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002287 · Cited by 246
Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
Ioerger, T. R., O’Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075245 · Cited by 241
Where Have all the Antibiotics Gone?
Davies, J. (2006) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2006/707296 · Cited by 228
Identification of a small molecule with activity against drug-resistant and persistent tuberculosis
Wang, F., Sambandan, D., Halder, R., Wang, J., Batt, S. M., Weinrick, B., Ahmad, I., Yang, P., Zhang, Y., Kim, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309171110 · Cited by 228
Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases
Li, K., Schurig-Briccio, L. A., Feng, X., Upadhyay, A., Pujari, V., Lechartier, B., Fontes, F. L., Yang, H., Rao, G., Zhu, W., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500131s · Cited by 223
Trefzer, C., Rengifo-Gonzalez, M., Hinner, M. J., Schneider, P., Makarov, V., Cole, S. T., & Johnsson, K. (2010) · Journal of the American Chemical Society · doi:10.1021/ja106357w · Cited by 215
Lee, R. E., Protopopova, M., Crooks, E., Slayden, R. A., Terrot, M., & Barry, C. E. (2003) · Journal of Combinatorial Chemistry · doi:10.1021/cc020071p · Cited by 207
Self-citationGene expression profile of Mycobacterium tuberculosis in a non-replicating state
Muttucumaru, D. G. N., Roberts, G., Hinds, J., Stabler, R. A., & Parish, T. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.12.006 · Cited by 205
Li, W., Upadhyay, A., Fontes, F. L., North, E. J., Wang, Y., Crans, D. C., Grzegorzewicz, A. E., Jones, V., Franzblau, S. G., Lee, R. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03229-14 · Cited by 202
Self-citationHernandez, V., Crépin, T., Palencia, A., Cusack, S., Akama, T., Baker, S. J., Bu, W., Feng, L., Freund, Y. R., Liu, L., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02058-12 · Cited by 196
Delamanid: First Global Approval
Ryan, N. J., & Lo, J. H. (2014) · Drugs · doi:10.1007/s40265-014-0241-5 · Cited by 191
Antibacterial targets in fatty acid biosynthesis
Wright, H. T., & Reynolds, K. A. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2007.07.001 · Cited by 189
Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux
Lee, R. E., Hurdle, J. G., Liu, J., Bruhn, D. F., Matt, T., Scherman, M. S., Vaddady, P. K., Zheng, Z., Qi, J., Akbergenov, R., et al. (2014) · Nature Medicine · doi:10.1038/nm.3458 · Cited by 188
Self-citationTowards a new tuberculosis drug: pyridomycin – nature's isoniazid
Hartkoorn, R. C., Sala, C., Neres, J., Pojer, F., Magnet, S., Mukherjee, R., Uplekar, S., Boy‐Röttger, S., Altmann, K., & Cole, S. T. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201689 · Cited by 188
New Targets and Screening Approaches in Antimicrobial Drug Discovery
Brown, E. D., & Wright, G. D. (2005) · Chemical Reviews · doi:10.1021/cr030116o · Cited by 186
Wolucka, B. A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06395.x · Cited by 182
The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
Mdluli, K., Kaneko, T., & Upton, A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021154 · Cited by 180
Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052951 · Cited by 177
Schubert, O. T., Mouritsen, J., Ludwig, C., Röst, H. L., Rosenberger, G., Arthur, P. K., Claassen, M., Campbell, D. S., Sun, Z., Farrah, T., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.04.008 · Cited by 174
Approval of Novel TB Drug Celebrated—With Restraint
Cohen, J. (2013) · Science · doi:10.1126/science.339.6116.130 · Cited by 166 · cited 1×
“Bedaquiline has been associated with QT-prolongation and must be carefully combined with other drugs that share this risk, including fluoroquinolones, macrolides, clofazimine, or drugs that inhibit CYP3A4, which may increase its exposure [15].”
BackgroundPharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions
Kjellsson, M. C., Via, L. E., Goh, A., Weiner, D., Low, K. M., Kern, S., Pillai, G., Barry, C. E., & Dartois, V. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05208-11 · Cited by 164
Shirude, P. S., Shandil, R., Sadler, C., Naik, M., Hosagrahara, V., Hameed, S., Shinde, V., Bathula, C., Humnabadkar, V., Kumar, N., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401382v · Cited by 164
De Lorenzo, S., Alffenaar, J. W., Sotgiu, G., Centis, R., D'Ambrosio, L., Tiberi, S., Bolhuis, M. S., van Altena, R., Viggiani, P., Piana, A., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00124312 · Cited by 160
The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis
Luciani, F., Sisson, S. A., Jiang, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902437106 · Cited by 156
Dubée, V., Triboulet, S., Mainardi, J.-L., Ethève-Quelquejeu, M., Gutmann, L., Marie, A., Dubost, L., Hugonnet, J.-E., & Arthur, M. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00665-12 · Cited by 153
A Steric Block in Translation Caused by the Antibiotic Spectinomycin
Borovinskaya, M. A., Shoji, S., Holton, J. M., Fredrick, K., & Cate, J. H. D. (2007) · ACS Chemical Biology · doi:10.1021/cb700100n · Cited by 153
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits
Wunberg, T., Hendrix, M., Hillisch, A., Lobell, M., Meier, H., Schmeck, C., Wild, H., & Hinzen, B. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03700-1 · Cited by 152
Indoleamides are active against drug-resistant Mycobacterium tuberculosis
Lun, S., Guo, H., Onajole, O. K., Pieroni, M., Gunosewoyo, H., Chen, G., Tipparaju, S. K., Ammerman, N. C., Kozikowski, A. P., & Bishai, W. R. (2013) · Nature Communications · doi:10.1038/ncomms3907 · Cited by 151
Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis
Rao, S. P. S., Lakshminarayana, S. B., Kondreddi, R. R., Herve, M., Camacho, L. R., Bifani, P. J., Kalapala, S. K., Jiřiček, J., Ma, N. L., Tan, B. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007355 · Cited by 148
Park, S. W., Klotzsche, M., Wilson, D. J., Boshoff, H. I., Eoh, H., Manjunatha, U. H., Blumenthal, A., Rhee, K. Y., Barry, C. E., Aldrich, C. C., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002264 · Cited by 146
Cerebrospinal Fluid Drug Concentrations and the Treatment of Tuberculous Meningitis
Ellard, G. A., Humphries, M. J., & Allen, B. W. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/148.3.650 · Cited by 141
Lee, R. E., Jr., Mikušová, K., Brennan, P. J., & Besra, G. S. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00153a002 · Cited by 140
Direct inhibitors of InhA are active against Mycobacterium tuberculosis
Manjunatha, U. H., Rao, S. P. S., Kondreddi, R. R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010597 · Cited by 137
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
Riccardi, G., Pasca, M. R., Chiarelli, L. R., Manina, G., Mattevi, A., & Binda, C. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5218-x · Cited by 130
Kaplan, N., Albert, M., Awrey, D. E., Bardouniotis, E., Berman, J., Clarke, T. E., Dorsey, M., Hafkin, B., Ramnauth, J., Romanov, V., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-12 · Cited by 120
Imipenem for Treatment of Tuberculosis in Mice and Humans
Chambers, H. F. “., Turner, J., Schecter, G. F., Kawamura, M., & Hopewell, P. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2816-2821.2005 · Cited by 114
Lu, H., England, K., Ende, C. W. A., Truglio, J. J., Luckner, S. R., Reddy, B. G., Marlenee, N. L., Knudson, S. E., Knudson, D. L., Bowen, R. A., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb800306y · Cited by 113
Amoxicillin-Clavulanic Acid for Treating Drug-Resistant Mycobacterium tuberculosis
Nadler, J. P., Berger, J., Nord, J. A., Cofsky, R., & Saxena, M. (1991) · CHEST Journal · doi:10.1378/chest.99.4.1025 · Cited by 112
The complex evolution of antibiotic resistance in Mycobacterium tuberculosis
da Fonseca, J. D., Knight, G. M., & McHugh, T. D. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.01.014 · Cited by 110
Shirude, P. S., Madhavapeddi, P., Naik, M., Murugan, K., Shinde, V. N., Nandishaiah, R., Bhat, J., Kumar, A., Hameed, S., Holdgate, G. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012033 · Cited by 108
The structure–activity relationship of urea derivatives as anti-tuberculosis agents
Brown, J. R. C., North, E. J., Hurdle, J. G., Morisseau, C. H. P., Scarborough, J. S., Sun, D., Korduláková, J., Scherman, M. S., Jones, V. M., Grzegorzewicz, A. E., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.034 · Cited by 106
Self-citationDhar, N., Dubée, V., Ballell, L., Cuinet, G., Hugonnet, J., Signorino‐Gelo, F., Barros, D., Arthur, M., & McKinney, J. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03461-14 · Cited by 105
Dooley, K. E., Obuku, E. A., Durakovic, N., Belitsky, V., Mitnick, C. D., Nuermberger, E. L., & on behalf of the Efficacy Subgroup, R.-T. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis460 · Cited by 102
Payen, M. C., Wit, S. D., Martin, C., SERGYSELS, R., Muylle, I., Laethem, Y. V., & Clumeck, N. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.11.0414 · Cited by 100
Esposito, S., D’Ambrosio, L., Tadolini, M., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00060414 · Cited by 99
Michot, J.-M., Seral, C., Françoise Van Bambeke, A., Mingeot‐Leclercq, M., & Tulkens, P. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2429-2437.2005 · Cited by 97
Poce, G., Bates, R. H., Alfonso, S., Cocozza, M., Porretta, G. C., Ballell, L., Rullás, J., Ortega, F., Logu, A. D., Agus, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056980 · Cited by 95
Goldman, R. C. (2013) · Tuberculosis · doi:10.1016/j.tube.2013.09.003 · Cited by 94
Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents
Shirude, P. S., Shandil, R. K., Manjunatha, M. R., Sadler, C., Panda, M., Panduga, V., Reddy, J., Saralaya, R., Nanduri, R., Ambady, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500571f · Cited by 89
Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase
Hu, Q., Liu, R., Fang, Z., Zhang, J., Ding, Y., Tan, M., Wang, M., Pan, W., Zhou, H., & Wang, E. (2013) · Scientific Reports · doi:10.1038/srep02475 · Cited by 87
Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis
Wivagg, C. N., Bhattacharyya, R. P., & Hung, D. T. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.94 · Cited by 85
Repurposing—a ray of hope in tackling extensively drug resistance in tuberculosis
Maitra, A., Bates, S., Kolvekar, T. S., Devarajan, P. V., Guzman, J. D., & Bhakta, S. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.12.031 · Cited by 84
The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound
Escaich, S., Prouvensier, L., Saccomani, M., Durant, L., Oxoby, M., Gerusz, V. J., Moreau, F., Vongsouthi, V., Maher, K., Morrissey, I., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01248-10 · Cited by 84
Pharmacokinetic interaction between rifampin and zidovudine
Burger, D. M., Meenhorst, P. L., Koks, C. H. W., & Beijnen, J. H. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.7.1426 · Cited by 81
Šink, R., Sosič, I., Živec, M., Fernandez-Menendez, R., Turk, S., Pajk, S., Álvarez-Gómez, D., López-Román, E. M., González‐Cortés, C., Rullas-Triconado, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501029r · Cited by 81
Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA
Hartkoorn, R. C., Pojer, F., Read, J. A., Gingell, H., Neres, J., Horlacher, O. P., Altmann, K., & Cole, S. T. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1405 · Cited by 74
Ashtekar, D. R., Costa-Periera, R., Shrinivasan, T., Iyyer, R., Vishvanathan, N., & RITTEL, W. (1991) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(91)90002-w · Cited by 74
Li, H., Lai, C., Pan, P., Yu, W., Liu, N., Bommineni, G. R., García–Díaz, M., Simmerling, C. L., & Tonge, P. J. (2014) · ACS Chemical Biology · doi:10.1021/cb400896g · Cited by 71
Tuberculosis and HIV Co-Infection
Breen, R. A. M., Swaden, L., Ballinger, J., & Lipman, M. C. I. (2006) · Drugs · doi:10.2165/00003495-200666180-00003 · Cited by 67
Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis.
Ellard, G. A., Humphries, M. J., Gabriel, M., & Teoh, R. (1987) · BMJ · doi:10.1136/bmj.294.6567.284 · Cited by 66
Activity of SQ641, a Capuramycin Analog, in a Murine Model of Tuberculosis
Nikonenko, B. V., Reddy, V. M., Protopopova, M. N., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-09 · Cited by 63
Gold, B. S., Warrier, T., & Nathan, C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2450-9_18 · Cited by 62
Lounis, N., Gevers, T., Berg, J. V. D., & Andries, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00566-08 · Cited by 60
Molecular Basis of Drug Resistance in Mycobacterium tuberculosis
Cohen, K. A., Bishai, W. R., & Pym, A. S. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0036-2013 · Cited by 52
Moraski, G. C., Miller, P. A., Bailey, M. A., Ollinger, J., Parish, T., Boshoff, H. I., Cho, S., Anderson, J. R., Mulugeta, S., Franzblau, S. G., et al. (2014) · ACS Infectious Diseases · doi:10.1021/id500008t · Cited by 50
(2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2450-9 · Cited by 50
Zhang, D., Wang, Y., Lu, J. L., & Pang, Y. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01035-15 · Cited by 47
Trends in discovery of new drugs for tuberculosis therapy
Riccardi, G., & Pasca, M. R. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.109 · Cited by 45
Kehrenberg, C., & Schwarz, S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00229-07 · Cited by 44
Lai, C., Li, H., Yu, W., Shah, S., Bommineni, G. R., Perrone, V., García–Díaz, M., Tonge, P. J., & Simmerling, C. L. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00284 · Cited by 42
Hazra, S., Xu, H., & Blanchard, J. S. (2014) · Biochemistry · doi:10.1021/bi500339j · Cited by 42
Construction of Conditional Knockdown Mutants in Mycobacteria
Schnappinger, D., O’Brien, K. M., & Ehrt, S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2450-9_9 · Cited by 40
Biava, M., PORRETTA, G. C., & Manetti, F. (2006) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707779317786 · Cited by 39
Salomon, J. J., Galeron, P., Schulte, N. E., Morow, P. R., Severynse-Stevens, D., Huwer, H., Schneider‐Daum, N., Lehr, C., Hickey, A. J., & Ehrhardt, C. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.62 · Cited by 38
Old and new drugs for the treatment of tuberculosis in children
Donald, P. R., & Schaaf, H. S. (2007) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2007.04.001 · Cited by 36
Clinical implications of the global multidrug-resistant tuberculosis epidemic
Kumar, K., & Abubakar, I. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-s37 · Cited by 20
Advances in Drug Discovery and Development for Pediatric Tuberculosis
Hoagland, D. T., Zhao, Y., & Lee, R. E., Jr. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150722101723 · Cited by 15
Self-citation
Cited by
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
(2023) · doi:10.1002/prot.26504 · Cited by 2
Metadata
- Authors
- Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 102
- Pages
- 55-72
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2405245899
- Cited by
- 328
- References
- 115
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.